Can-Fite BioPharma(CANF.US)

Last Updated 19:00:00 ET
longbridge loading

Can-Fite (CANF.US) sees volatility, shares down intraday

Movers Alert·
US
CANF
-0.58%
US
IXJ
+0.67%
US
ARKG
+3.35%
Movers Alert·
US
CANF
-0.58%
US
IXJ
+0.67%
US
ARKG
+3.35%

Can-Fite BioPharma Rallies 24% on Positive Trial Data

Movers Alert·
US
CANF
-0.58%
Movers Alert·
US
CANF
-0.58%

Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months | CANF Stock News

StockTitan·
US
CANF
-0.58%
StockTitan·
US
CANF
-0.58%

Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026 | CANF Stock News

StockTitan·
US
LABU
+2.48%
US
IBB
+0.68%
US
BBH
+0.64%
StockTitan·
US
LABU
+2.48%
US
IBB
+0.68%
US
BBH
+0.64%

Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient | CANF Stock News

StockTitan·
US
CANF
-0.58%
StockTitan·
US
CANF
-0.58%

Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance | CANF Stock News

StockTitan·
US
CANF
-0.58%
StockTitan·
US
CANF
-0.58%
© 2026 Longbridge｜Disclaimer